15 Cheapest Stocks Insiders Are Buying In March

10. Alzamend Neuro, Inc. (NASDAQ:ALZN)

Market Capitalization: $6.73 million

Alzamend Neuro, a clinical-stage biopharmaceutical company, ranks 10^th among the 15 cheapest stocks insiders are buying this month. The Atlanta, Georgia-headquartered company focuses on developing treatments for neurodegenerative and psychiatric disorders. Its pipeline includes AL001, a combination therapy for Alzheimer’s and other mental health conditions, and ALZN002, a cell-based therapeutic vaccine for Alzheimer’s. The company partners with Massachusetts General Hospital for AL001’s Phase II clinical trial.

The company recently announced plans to begin a Phase II clinical study of AL001 for the treatment of patients with Major Depressive Disorder (MDD) in the fourth quarter of 2025. This follows the successful completion of a head coil by Tesla Dynamic Coils BV, a crucial component for the trial. In partnership with Massachusetts General Hospital as its contract research organization, Alzamend aims to investigate the unique properties of AL001 and its effects on lithium delivery in the brain compared to existing lithium salts.

This month, two insiders, including the CFO, purchased around $14,621 worth of Alzamend Neuro shares at an average price of $0.90 per share. Since the beginning of the year, Alzamend shares have declined 12.07%, trading at $1.02. Over the past 12 months, Alzamend lost 89.90%.

StockAnalysis reports that one analyst has rated Alzamend Neuro stock as a “Strong Buy” with a price target of $20.00.